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Abstract
To date, the advantage of adjuvanted over non-adjuvanted vaccines in the specific anti-
bodies formation is proved. However, cellular mechanisms, including parameters of 
the innate immunity, involved in the vaccine-induced immune response are not well 
studied. The human study of inactivated vaccines showed that both subunit vaccine 
and split vaccine induced cellular immune response, but adjuvanted vaccine containing 
Polyoxidonium had the greatest potential. Despite the fact that influenza vaccines must 
activate endosomal receptors, they cause non-specific activation of the surface TLRs. They 
can trigger intracellular signals leading to the induction of antiviral mechanisms and to 
the activation of the body’s protective resources against microbial infections. To assess the 
immunological efficacy of adjuvanted vaccines and humoral reactions to vaccination it is 
necessary to evaluate activation of cellular mechanisms of innate and adaptive immunity.
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1. Introduction
Vaccination is the most effective means of preventing influenza and consequently reducing 
incidence and severity of complications. Modern influenza vaccines include a live attenuated, 
inactivated (whole-virion, split-virion and subunit) vaccines. Currently, inactivated split and 
subunit vaccines are used for influenza prevention as the safest ones and stimulating the 
production of a protective level of strain-specific virus-neutralizing antibodies to the globular 
domain of hemagglutinin protein and neuraminidase protein of contemporary serotypes of 
the influenza virus. These vaccines protect against infection with the appropriate antigenic 
variants of influenza virus. Not all inactivated vaccines have been reported to be effective 
enough for certain categories of vaccinated people [1–7]. Some of them are not able to protect 
against drift variants of influenza virus [8–11].
Due to the continuous antigenic drift of influenza viruses and the emergence of pandemic 
influenza viruses, the study of influenza vaccines causing broader protective immunity is of 
great interest [12]. In this regard, before influenza pandemic of 2009–2010 vaccination with 
adjuvanted vaccines began, aiming to enhance the synthesis of specific antibodies. In addi-
tion, given poor population health in the modern era, there is the need to enhance the efficacy 
of vaccines meant to activate all the components of the immune system. According to the 
literature data, adjuvanted vaccines seem to have such effect. However, a small number of 
human studies to investigate, how adjuvanted vaccine influence cellular immunity and acti-
vate of not only adaptive, but also innate immunity, have been conducted. In addition, unlike 
foreign adjuvanted influenza vaccines developed in 2009–2010, the National Immunization 
Calendar of the Russian Federation for more than 20 years applies polymer-subunit influenza 
vaccine containing immunomodulator PO as the adjuvant. Furthermore, immunomodulators 
have long been used in vaccination practice for immunocompromised patients in the Russian 
Federation. Immunomodulator use to support the vaccination was shown to promptly 
enhance the synthesis of specific antibodies and significantly decrease the incidence of respi-
ratory infections in the postvaccinal period [13–15].
To date, the vaccine immunogenicity is assessed according to the requirements of the 
European Committee for influenza vaccines [16], and must meet at least one of the three 
criteria:
• seroconversion (percentage of subjects with a fourfold increase in antibody titers after vac-
cination)—at least 40%;
• seroprotection (percentage of subjects with a protective antibody titers before and 
21–28 days after vaccination)—at least 70% and
• multiplicity factor for the increase of antibody titers compared to baseline—at least 2.5.
Taking into account a new type of vaccine (adjuvanted), not only humoral, but also cellular 
immune response is important for the evaluation of immunological efficacy. The activation 
of cellular immunity parameters, important to the formation of immunological memory, may 
differ from that of non-adjuvanted vaccines.
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The aim of the study was to examine the effect of immunoadjuvant-containing and non-
adjuvanted influenza vaccines on the immunophenotype of healthy donor lymphocytes and 
the number of cells with toll-like receptor expression in vitro.
2. Materials and methods
2.1. Clinical characteristics of patients
An open-label non-randomized monocenter study enrolled 27 healthy women of childbear-
ing potential (aged 18–40 years) without co-morbidities who were not influenza-vaccinated 
within the previous 3 years and acquired no influenza or influenza-like illnesses within the 
previous 6 months.
2.2. Legal basis of the study
Once the signed informed consent for study participation was obtained, venous blood 
samples were drawn from volunteers with all applied aseptic and antiseptic techniques met 
and in accordance with the Study Protocol approved in 2015 by the Ethics Committee at the 
Mechnikov Research Institute of Vaccines and Sera. The study was conducted at the certified 
laboratory of the Mechnikov Research Institute of Vaccines and Sera (Moscow) using modern 
reagents and equipment.
2.3. Distribution pattern of lymphocyte subpopulations
The distribution pattern of peripheral blood lymphocyte subpopulations in vitro in healthy 
women exposed to influenza vaccine was tested by flow cytometer FC-500 (Beckman Coulter, 
USA), using anti-CD45/CD3, anti-CD45/CD3/CD4, anti-CD45/CD3/CD8, anti-CD16/56, anti-CD3/
CD16/56, anti-CD45/CD20, anti-CD8/HLA-DR, anti-CD3/HLA-DR, anti-CD45/CD25, and anti-СD4/
CD25/Foxp3 FITC- and PE-labeled monoclonal antibodies mAbs (Beckman Coulter, USA).
2.4. Toll-like receptors
The concentration of granulocytes with TLR expression was evaluated by flow cytometer 
FC-500 (Beckman Coulter, USA) using anti-TLR2, anti-TLR 3, anti-TLR4, anti-TLR6, anti-
TLR8, and anti-TLR9 mAbs (eBioscience, USA).
Mononuclear WBCs were isolated from the whole blood using Ficoll-Urografin density gra-
dients. We incubated 106 cells/mL in RPMI-1640 complete growth medium (PanEco, Russia) 
with 10% FBS (PanEco, Russia) and antibiotic (streptomycin) in the presence of 10 μL of a 
corresponding vaccine for 72 hours.
2.5. Study vaccines
Influvac (“Abbott biologicals” B.V., Netherlands) – inactivated subunit influenza vaccine, 
Vaxigrip (“Sanofi Pasteur”, France)– inactivated split-virion influenza vaccine for influenza 
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prevention. These vaccines contain hemagglutinin of the influenza virus type A subtypes 
A/H1N1 и A/H3N2 (15 μg each) and hemagglutinin of the influenza virus type B (15 μg). 
Grippol plus (LLC “NPO Petrovax Pharm,” Russia) – trivalent polymer subunit inactivated 
influenza vaccine. It contains hemagglutinin of the influenza virus type A subtypes A/H1N1 
и A/H3N2 and hemagglutinin of the influenza virus type B (5 μg each), and immunoadjuvant 
Polyoxidonium (500 μg). All the vaccines contained current influenza virus strains for epide-
miological seasons 2015–2016 and 2016–2017.
Anti-influenza virus A/H1N1/California/07/09, p.149, A/H3N2/Switzerland/9715293/13 (subunit 
antigen), B/Phuket/3073/13, p. 25 (season 2015–2016); A/H1N1/California/07/09 p.124 till 01.17, A/
H3N2/Hong Kong/4801/14 p.200, and B/Brisbane/60/08 p. 27 (season 2016–2017) baseline serum 
antibody levels were studied in volunteers using the standard method (MU 3.3.2 1758–03) for 
HAI assay. The 4+ system was applied to HAI assay: an antigen titer, i.e., 1 HAU, was highest 
antigen dilution giving complete hemagglutination of RBCs (3+ or 4+). In HAI assay the antigen 
working dose was the antigen dilution containing 4 hemagglutination units (4 HAU) in 0.2 mL.
2.6. Statistical analysis
Cell percentage difference between test groups was measured by a robust dispersion analysis 
of repeated measures (R Statistical Software, WRS2 package, rmanova function) with sub-
sequent pairwise comparisons (R Statistical Software, WRS2 package, rmmcp function), the 
obtained significance level was corrected by Holm method [17]. Benjamini-Hoсhberg method 
was used to account for multiple comparison (false discovery rate control) [18]. The obtained 
data were described with the median and interquartile range.
3. Study results
First, we estimated vaccine effect on distribution pattern of lymphocyte subpopulations in 
PBMC cultures. Volunteers were divided into three groups according to the baseline antibody 
(AB) titers against the hemagglutin of the influenza virus A/H1N1, A/H3N2, and B: low AB 
titers (20–40 U) in the first group, medium AB titers (80–160 U) in the second group, and high 
AB titers (≥320 U) in the third group. Such differences in AB level indicate that influenza 
infection in the unvaccinated volunteers could have been masked under the guise of another 
infection, as all volunteers did not report previous influenza infection.
Immunophenotypic analysis showed changes in the number of T lymphocytes (СD45+/
СD3+), NK cells (CD16+/56+), NKT cells (CD3 + CD16/56+), B lymphocytes (СD45+/CD20+), 
and activated cells (Table 1).
There were statistically significant differences (F = 8.00, p < 0.001, q = 0.001) in T lymphocytes 
(СD3+) distribution after incubation with different types of vaccines (Figure 1). It should be 
noted that regardless of the AB level vaccines did not have a significant effect on T lympho-
cyte number except subunit vaccine, which caused a decrease in the percent of T lympho-
cytes compared to control (PBMC culture without vaccine) while the absolute number did 
not change. These results may indicate a shift in the number of cells due to an increase in the 
number of other subpopulations.
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Lymphocyte 
subpopulations
N % in comparison groups – Me(Q1–Q3) F p q
Control Subunit 
V
Adjuvanted 
V
Split-
product V
T lymphocytes
(CD45/СD3+)
18 79.85
(74.17–
83.35)
71.25
(64.7–
79.75)
74.6
(66.38–79.17)
73.91
(66.92–
78.22)
8.00 <0.001 0.001
Helper T cells
(CD45/CD3/СD4+)
21 43.5
(41–49.8)
37.5
(32.7–
43.8)
40.2
(31.8–46.5)
41.9
(35.6–47.7)
2.50 0.071 0.107
Cytotoxic
T lymphocytes, CTL
(CD45/CD3/СD8+)
21 23.5
(17.3–24.7)
21.2
(17.4–
23.6)
22.5
(16.9–26.9)
21.5
(18.4–5.8)
0.64 0.533 0.601
Natural killer
cells, NK cells
(CD16/56+)
24 4.85
(4.175–5.9)
13.2
(11.15–
14.85)
17.25
(15.93–18.25)
15
(13.8–16.25)
180.28 <0.001 <0.001
Natural killer
T cells, NKT
(CD3/CD16/56+)
24 1.6
(1.3–2.25)
3.6
(2.775–
5.825)
7.5
(6.675–8.225)
5
(4.625–6.75)
57.52 <0.001 0.00001
B lymphocytes
(CD45/CD20+)
24 5.15
(4.475–
6.725)
16.36
(15.47–
17.7)
21.15
(18.93–22.9)
18.1
(15.88–
19.62)
167.44 <0.001 <0.001
Activated
cytotoxic
T lymphocytes, 
CTL(CD8/HLA-DR+)
20 0.4
(0.275–0.5)
0.7
(0.3–1.2)
1.6
(1.2–2.4)
1.35
(0.4875–
1.975)
13.36 <0.001 <0.001
Activated
T lymphocytes
(CD3/HLA-DR+)
12 1.05
(0.65–1.65)
2.7
(1.875–
3.375)
4.95
(3.775–7.1)
2.6
(1.9–3.575)
8.92 <0.001 0.002
Activated
lymphocytes
(CD45/CD25+)
16 1.45
(1–1.775)
3.7
(2.6–4.85)
4.15
(3.2–9.075)
4.15
(3.075–
5.275)
12.94 <0.001 0.001
Regulatory T cells, 
Tregs
(CD4/CD25/Foxp3+)
13 2.7
(1.7–2.9)
3.5
(3.2–4.9)
3.7
(3.2–5.5)
4.2
(2.2–4.5)
4.27 0.017 0.032
IRI
(CD4/CD8)
20 1.825
(1.5–3.275)
1.85
(1.45–
2.325)
1.85
(1.4–2.5)
1.65
(1.475–.525)
1.26 0.300 0.389
Note. Aliquots of 10 μL vaccines were added to cell suspensions (PBMC, 106 cells/mL). Cells were incubated for 72 hours 
at 37°С in 5% СО
2
. The cells were then washed with RPMI-1640 at 1500 g for 10 min. Monoclonal antibodies against 
studied cell receptors were added in accordance with the manufacturer’s instructions. The number of cells (%) in each 
sample was determined by flow cytometry.
Table 1. Distribution pattern of peripheral blood lymphocyte subpopulations incubated with influenza vaccines.
The Impact of Adjuvanted and Non-Adjuvanted Influenza Vaccines on the Innate and Adaptive…
http://dx.doi.org/10.5772/intechopen.77006
87
The comparison of the T lymphocyte count between vaccines showed a significant decrease 
in the number of cells after incubation with subunit vaccine only (71.2% vs. 79.8% in control, 
p = 0.008) (Figure 1). However, the changes in the T lymphocyte (СD3+) number after incuba-
tion with different types of vaccines were observed only in women with medium AB level 
(F = 6.40, p = 0.004, q = 0.007). In this group, statistically significant differences were found for 
subunit vaccine (72 vs. 82.6% in control, p = 0.022) and split-product vaccine (74.8 vs. 82.6% in 
control, p = 0.022) (Figure 2).
Figure 1. Lymphocyte count in PBMC culture after incubation with influenza vaccines. C = control; Su = inactivated 
subunit influenza vaccine; A = trivalent inactivated polymer-subunit influenza vaccine; Sp = inactivated split-product 
influenza vaccine.
Figure 2. The impact of influenza vaccines on the lymphocyte count in PBMC cultures from volunteers with different 
antibody titers against the hemagglutinin of the influenza virus a/H1N1, a/H3N2, and В. Significant differences: *** 
p < 0.001, ** p < 0.01, * p < 0.05.
Influenza - Therapeutics and Challenges88
Analysis revealed significant changes (F = 180.28, p < 0.001, q < 0.001) in percent of natural 
killer cells (NK, CD16/56+) after incubation with different types of vaccines (Table 1, Figure 1). 
Regardless of the AB level there was an increase in number of NK cells from 4.8 (control) to 
13.2% (subunit vaccine), 17.2% (adjuvanted vaccine), and 15% (split vaccine). There were sta-
tistically significant differences for subunit (13.2 vs. 4.8%, p < 0.001), adjuvanted (17.2 vs. 4.8%, 
p < 0.001), and split vaccines (15 vs. 4.8%, p < 0.001) compared to control, for subunit vaccine 
compared to adjuvanted (13.2% vs. 17.2%, p < 0.001) and split vaccines (13.2 vs. 15%, p = 0.003), 
and for adjuvanted vaccine compared to split vaccine (17.2 vs. 15%, p < 0.001). That means that 
incubation with influenza vaccines increased the number of NK cells in all cultures.
However, the changes in number of NK cells (CD16/56+) after incubation of PBMC with dif-
ferent types of vaccines were observed in all groups of volunteers, regardless of the baseline 
anti-influenza AB level (F = 48.88, p < 0.001, q < 0.001 – low AB level, F = 103.04, p < 0.001, 
q < 0.001 – medium AB level, F = 89.09, p < 0.001, q < 0.001 – high AB level) (Figure 2).In women 
with low anti-influenza AB level, percent of NK cells (CD16/56+) was significantly higher after 
incubation with subunit (11 vs. 5%, p = 0.045), adjuvanted (16.5% vs. 5%, p = 0.001), and split 
vaccines (14.2 vs. 5%, p = 0.01) compared to control. Immunoadjuvant-containing vaccine had 
a higher potential for elevation of NK cell number (3.3-fold increase) compared with subunit 
vaccine (2.2-fold increase) (p = 0.017).
In women with medium anti-influenza AB level, percent of NK cells (CD16/56+) was sig-
nificantly higher after incubation with subunit (12.8 vs. 4.8%, p = 0.001), adjuvanted (17.5 vs. 
4.8%, p < 0.001), and split vaccines (15.3 vs. 4.8%, p < 0.001) compared to control. This cor-
responds to a 2.6- to 3.6-fold increase. Immunoadjuvant-containing vaccine produced more 
pronounced increase compared to subunit vaccine (17.5 vs. 12.8%, p = 0.029) and split vaccine 
(17.5 vs. 15.3%, p = 0.011), and number of NK cells was significantly higher after incubation 
with split vaccine compared to subunit vaccine (15.3 vs.12.8%, p = 0.029).
In women with high anti-influenza AB level, percent of NK cells (CD16/56+) was significantly 
higher after incubation with subunit (14.8 vs. 4.4%, p = 0.023), adjuvanted (18.2 vs. 4.4%, 
p = 0.046), and split vaccines (16.1 vs. 4.4%, p = 0.035) compared to control. This corresponds 
to a 3.3-, 4.1-, and 3.6-fold increase, respectively. There were no statistically significant differ-
ences between various types of vaccines.
For NKT cells (natural killer Т cells, CD3 + CD16/56+), following findings were revealed. 
Regardless of the AB level there were statistically significant changes (F = 57.52, p < 0.001, 
q < 0.001) in NKT cells distribution after incubation with different types of vaccines: for sub-
unit (3.6 vs. 1.6%, p = 0.006), adjuvanted (7.5 vs. 1.6%, p < 0.001), and split vaccines (5 vs. 1.6%, 
p < 0.001) compared to control, for subunit vaccine compared to adjuvanted (3.6 vs. 7.5%, 
p < 0.001) and split vaccines (3.6 vs. 5%, p = 0.007), and for adjuvanted vaccine compared to 
split vaccine (7.5 vs. 5%, p = 0.006). Therefore, subunit vaccine caused a 2.2-fold increase in 
NKT cell number, adjuvanted vaccine caused a 4.6-fold increase, and split vaccine caused a 
3.1-fold increase compared to control (Table 1, Figure 1).
An increase of NKT cell (CD3 + CD16/56+) number in all cultures was dependent of baseline 
anti-influenza AB level (F = 22.08, p < 0.001, q < 0.001 – low AB level, F = 20.02, p < 0.001, 
q < 0.001 – medium AB level, F = 65.92, p < 0.001, q < 0.001 – high AB level) (Figure 2).
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In women with low anti-influenza AB level, NKT cell (CD16/56+) number was significantly 
higher after in vitro incubation with subunit (7 vs. 1.6%, p = 0.033), adjuvanted (8.1 vs. 1.6%, 
p = 0.007), and split vaccines (5 vs. 1.6%, p = 0.005) compared to control. There were no statisti-
cally significant differences between various types of vaccines.
In women with medium anti-influenza AB level, NKT cell number in PBMC cultures was 
significantly higher after incubation with adjuvanted vaccine compared to control (7.4 vs. 
1.3%, p < 0.001) and subunit vaccine (7.4 vs. 3%, p < 0.001) (5.7- and 2.48-fold increase, respec-
tively) and after incubation with split vaccine compared to control (4.4 vs. 1.3%, p < 0.001) and 
subunit vaccine (4.4 vs. 3%, p = 0.009) (3.38- and 1.46-fold increase, respectively).
In women with high anti-influenza AB level, percent of NKT cells (CD3 + CD16/56+) was 
significantly (4.6-fold) higher after incubation with adjuvanted vaccine compared to control 
(7.4 vs. 1.6%, p = 0.043).
Analysis also revealed statistically significant differences (F = 167.44, p < 0.001, q < 0.001) in 
B lymphocytes (CD45/CD20+) distribution after incubation of PBMC with different types of 
vaccines (regardless of the AB level): for subunit (16.3 vs. 5.1%, 3.1-fold increase, p < 0.001), 
adjuvanted (21.1 vs. 5.1%, 4.1-fold increase, p < 0.001), and split vaccines (18.1 vs. 5.1%, 3.5-
fold increase, p < 0.001) compared to control, and for adjuvanted vaccine compared to subunit 
(21.1 vs. 16.3%, 1.3-fold increase, p < 0.001) and split vaccines (21.1 vs. 18.1%, 1.1-fold increase, 
p < 0.001). Therefore, adjuvanted vaccine was the most effective (Table 1, Figure 1).
Regardless of the AB level there was a significant increase in B lymphocyte number after 
incubation with different types of vaccines (F = 24.09, p < 0.001, q < 0.001 – low AB level, 
F = 181.14, p < 0.001, q < 0.001 – medium AB level, F = 150.61, p < 0.001, q < 0.001 – high 
AB level) (Figure 2). In women with low anti-influenza AB level, percent of B lymphocytes 
(CD20+) was significantly higher after incubation with subunit (15.6 vs. 5%, p = 0.017), adju-
vanted (16.3 vs. 5%, p = 0.046), and split vaccines (14.7 vs. 5%, p = 0.014) compared to control. 
There were no statistically significant differences between various types of vaccines.
In women with medium anti-influenza AB level, percent of B lymphocytes (CD20+) was 
also significantly higher after incubation with all types of vaccines: subunit (16.2 vs. 5.3%, 
p < 0.001), adjuvanted (21.6 vs. 5.3%, p < 0.001), and split vaccines (18.1 vs. 5.3%, p < 0.001) 
compared to control. Immunoadjuvant-containing vaccine had the greatest potential for 
elevation of B lymphocyte number (21.6%) compared with subunit vaccine (16.2%, 1.3-fold 
increase) (p < 0.001) and split vaccine (18.1%, 1.2-fold increase) (p = 0.013).
In women with high anti-influenza AB level, there was a significant increase in B lympho-
cyte number after incubation with subunit (20 vs. 4.7%, p = 0.021), adjuvanted (23.6 vs. 4.7%, 
p = 0.030), and split vaccines (21.9 vs. 4.7%, p = 0.030) compared to control. Immunoadjuvant-
containing vaccine induced higher (fivefold) increase of B lymphocyte number than split vac-
cine (4.6-fold, p = 0.011).
Analysis revealed statistically significant differences (F = 13.36, p < 0.001, q < 0.001) in 
the distribution of activated cytotoxic T lymphocytes (CD8/HLA-DR+) after incubation 
of PBMC with different types of vaccines (regardless of the AB level) (Table 1, Figure 1). 
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Immunoadjuvant-containing and split vaccines more effectively increased the number 
of this type of cells. There were statistically significant changes for subunit (1.6 vs. 0.4%, 
p < 0.001), adjuvanted (1.3 vs. 0.4%, p = 0.050), and split vaccines (1.6 vs. 0.7%, p = 0.002) 
compared to control, for adjuvanted vaccine compared to subunit vaccine (1.3 vs. 0.7%, 
respectively, p = 0.046), and for adjuvanted vaccine compared to split vaccine (4.9 vs. 2.6%, 
respectively, p = 0.044).
However, changes in the number of activated cytotoxic T lymphocytes in vitro between vac-
cine types were significant only in women with medium anti-influenza AB level (F = 5.16, 
p = 0.020, q = 0.035) (Figure 2). Incubation with adjuvanted vaccine caused significant increase 
of the number of activated cytotoxic T lymphocytes compared to control (1.4 vs. 0.4%, 
p = 0.049) and subunit vaccine (1.4 vs. 0.7%, p = 0.047).
Regardless of the AB level there were significant changes in the number of Т lymphocytes 
with late activation marker (CD3/HLA-DR+) after incubation with different types of vaccines 
(F = 8.92, p < 0.001, q = 0.002) (Table 1, Figure 1). There were statistically significant changes 
for subunit (2.7 vs. 1%, p < 0.044), adjuvanted (4.9 vs. 1%, p = 0.006), and split vaccines (2.6 vs. 
1%, p = 0.010) compared to control, and for adjuvanted vaccine compared to subunit (4.9 vs. 
2.7%, p = 0.015) and split vaccines (4.9 vs. 2.6%, p = 0.044).
Statistically significant changes in the number of this type of cells were demonstrated only 
in women with low (F = 30.17, p < 0.001, q < 0.001) and high (F = 12.49, p = 0.001, q = 0.003) 
anti-influenza AB level (Figure 2). In women with low serum AB level, analysis of activated 
T lymphocytes showed significant activation by adjuvanted vaccine compared to control (3.8 
vs. 0.9%, p = 0.047). In women with high serum AB level, the number of activated T lympho-
cytes was significantly higher after incubation with adjuvanted vaccine compared to split 
vaccine (8.2 vs. 3.5%, p = 0.027) (Figure 2).
For lymphocytes with early activation marker (CD45/CD25+), there was statistically signifi-
cant increase (F = 12.94, p < 0.001, q = 0.001) after incubation of PBMC with different types of 
vaccines, regardless of the AB level (Table 1, Figure 1).All types of vaccines increased number 
of cells with early activation marker. Furthermore, there were statistically significant changes 
for subunit (3.7 vs. 1.4%, p = 0.007), adjuvanted (4.1 vs. 1.45%, p = 0.049), and split-product 
vaccines (4.1 vs. 1.4%, p = 0.003) compared to control. There were no statistically significant 
differences between various types of vaccines.
Regardless of the AB level there was a significant changes in the number of activated CD45/
CD25+ lymphocytes. It was dependent of the vaccine type in all groups of volunteers (F = 9.96, 
p = 0.002, q = 0.006 – low AB level, F = 7.92, p = 0.002, q = 0.005 – medium AB level, F = 25.89, 
p < 0.001, q < 0.001 – high AB level) (Figure 2).
In women with low and medium AB level, percent of T lymphocytes with early activation 
marker (CD45/CD25+) was significantly increased after incubation of PBMC with subunit 
vaccine (3.8 and 3.3%, respectively) compared to control (1.1 and 1.2%, respectively) (p = 0.024 
and p = 0.036). At the same time, in women with high AB level, the number of these cells 
was increased after incubation of PBMC with adjuvanted vaccine (11%) compared to control 
(1.5%) (p = 0.009).
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Analysis also revealed significant changes (F = 4.27, p = 0.017, q = 0.032) in regulatory T cell 
(T-regs) number with CD4/CD25/Foxp3+ phenotype after incubation of PBMC with different 
types of vaccines, regardless of the AB level (Table 1, Figure 1). Immunoadjuvant-containing 
vaccine increased T-regs number compared to control (3.7 vs. 2.7%, 1.3-fold increase, 
p = 0.005). Other types of vaccines did not have a significant effect on these cells.
Significant changes in the number of T-regs between vaccine types were noted only in women 
with high AB level against influenza viruses A/H1N1, A/H3N2, and В (F = 8.15, p = 0.003, 
q = 0.006) (Figure 2).Incubation of PBMC with adjuvanted vaccine induced significant increase 
of T-regs count (CD25/CD4/Foxp3+) compared to control (5.5 vs. 2.7%, p = 0.049).
At the next step of the study we evaluated number of TLR-expressing granulocytes in PBMC 
cultures incubated with influenza vaccines.
All types of vaccines had immunostimulating effect on TLR-expressing cells by increasing the 
number of granulocytes expressing TLR 2,3,4,6,8, and 9, as shown in Table 2.
We found significant differences (F = 270.16, p < 0.001, q < 0.001) in the percent of granulocytes 
expressing TLR2 (Table 2, Figure 3) after incubation of PBMC with different types of vac-
cines, regardless of the AB level against the hemagglutinin of the influenza virus A/H1N1, 
A/H3N2 and В.. Subunit vaccine increased number of TLR2+ cells in PBMC culture from 
16.6 (in control) to 38.2% (p < 0.001), adjuvanted vaccine—to 39.8% (p < 0.001), and split vac-
cine—to 37.5% (p < 0.001). However, there were no significant differences in TLR2 cell number 
between vaccine types.
Incubation of cell culture in the presence of influenza vaccines induced an increase in the 
number of TLR2+ granulocytes regardless of the baseline anti-influenza AB level (F = 53.25, 
p < 0.001, q < 0.001 – low AB level, F = 169.63, p < 0.001, q < 0.001 – medium AB level, F = 103.89, 
p < 0.001, q < 0.001 – high AB level) (Figure 4). In women with low AB level, the number 
TLR N TLR-expressing granulocytes, %, Me (Q1-Q3) F p q
Control Subunit Adjuvanted Split
2 24 16.6 
(14.2–18.38)
38.2 
(36.45–40.05)
39.35 
(37.73–42.4)
37.5 
(35.38–39.27)
270.16 <0.001 <0.001
4 24 22.3 
(19.75–25.4)
26.85 
(25.23–29.43)
24.45 
(22.15–26.9)
23.35 
(21.5–25.35)
10.62 <0.001 <0.001
3 24 20.2 
(18.23–22.95)
20 
(18.02–24.05)
21.7 (19.5–23.05) 24.15 
(21.95–25.95)
6.90 <0.001 <0.001
9 24 11.95 
(9.825–12.85)
19.85 
(17.95–25.2)
25.45 (24–26.32) 26.4 
(24.48–28.23)
86.57 <0.001 <0.001
8 24 20.6 
(18.68–22.4)
32.7 (30.12–35) 42.5 (37–45.1) 34.4 (29–37) 138.59 <0.001 <0.001
6 23 4.3 (4.05–5.15) 6.5 (5.95–7) 5.7 (5.2–6.9) 6.9 (5.95–7.55) 18.04 <0.001 <0.001
Table 2. Number of TLR-expressing granulocytes after incubation with influenza vaccines.
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of TLR2-expressing granulocytes increased 2.4-fold after incubation with subunit vaccine 
(p
h
 = 0.019), 2.3-fold after incubation with adjuvanted vaccine (p
h
 = 0.019), and 2.2-fold after 
incubation with split vaccine (p
h
 = 0.003) compared with control.
In women with medium AB level, there was similar increase in the number of these cells: 2.3-
fold for subunit and split vaccines (p
h
 < 0.001), and 2.4-fold for adjuvanted vaccine (p
h
 = 0.001) 
compared with control.
In women with high AB level, the number of TLR2-expressing granulocytes increased 2.6-fold 
after incubation with subunit vaccine (p
h
 = 0.031), 2.8-fold after incubation with adjuvanted 
vaccine (p
h
 = 0.029), and 2.7-fold after incubation with split vaccine (p
h
 = 0.029) compared with 
control.
Analysis revealed significant differences (F = 10.62, p < 0.001, q < 0.001) in the percent of 
granulocytes expressing TLR4 after incubation of PBMC with different types of vaccines, 
regardless of the AB level against the hemagglutinin of the influenza virus (Table 2, Figure 3). 
Subunit vaccine increased number of TLR4+ cells 1.2-fold compared to control (p < 0.001) and 
1.1-fold compared to split vaccine (p < 0.001).
Statistically significant changes in the number of TLR4+ cells (Figure 4) between vaccine types 
were demonstrated only in women with medium AB level (F = 5.24, p = 0.008, q = 0.010): the 
number of these cells increased 1.1-fold after incubation with subunit vaccine compared to 
control (p
h
 = 0.047) and 1.2-fold compared to split vaccine (p = 0.007).
Figure 3. Number of TLR-expressing granulocytes in PBMC cultures incubated with influenza vaccines. C = control; 
Su = inactivated subunit influenza vaccine; A = trivalent inactivated polymer-subunit influenza vaccine; Sp = inactivated 
split-product influenza vaccine.
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Analysis of TLR3-expressing granulocytes (Table 2, Figure 3) revealed significant differences 
(F = 6.90, p < 0.001, q < 0.001) between groups, meaning that activation of the innate immunity 
effectors was dependent of the vaccine type, but not baseline AB level. There were significant 
differences for split vaccines compared to control (1.2-fold increase, p = 0.001) and subunit 
vaccine (1.2-fold increase, p = 0.008). That means that split vaccine had higher activity.
In women with low and high AB level, there were significant changes in the number of TLR3-
expressing cells (Figure 4). The significance of differences was (F = 6.05, p = 0.025, q = 0.030) 
for low AB level and (F = 6.45, p = 0.008, q = 0.010) for high AB level. In women with low and 
high AB level, percent of TLR3-expressing granulocytes significantly increased after incuba-
tion with split vaccine (1.3-fold, p
h
 = 0.042 and p
h
 = 0.050, respectively) compared to control.
Analysis also revealed (Table 2, Figure 3) that different vaccines influenced (F = 86.57, p < 0.001, 
q < 0.001) the number of TLR9-positive cells regardless of the AB level. All types of vaccines 
increased the number of TLR9-expressing granulocytes in PBMC culture. Subunit vaccine 
caused 1.6-fold increase (p < 0.001), adjuvanted vaccine caused 2.1-fold increase (p < 0.001), 
and split vaccine caused 2.2-fold increase (p < 0.001) compared to control. Subunit vaccine was 
1.2-fold less effective than adjuvanted vaccine (p = 0.012) and 1.3-fold less effective than split 
vaccine (p = 0.003).
Analysis showed that effect of different types of vaccines on TLR9-positive cells depended on 
the baseline AB level (F = 26.93, p < 0.001, q < 0.001 – low AB level; F = 39.81, p < 0.001, q < 0.001 
– medium AB level; F = 29.41, p < 0.001, q < 0.001 – high AB level) (Figure 4). In women with 
low AB level, split vaccine induced threefold increase in the number of TLR9+ granulocytes 
Figure 4. The impact of influenza vaccines on TLR-expressing granulocytes in PBMC cultures from volunteers with 
different AB titers against the hemagglutinin of the influenza virus A/H1N1, A/H3N2 and В.
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compared to PBMC culture without stimulation (p
h
 = 0.002). However, in women with medium 
and high AB level, other types of vaccines stimulated TLR9+ granulocytes. There were follow-
ing differences between vaccine types: subunit vaccine caused 1.6-fold increase (p
h
 = 0.017, 
p
h
 = 0.050), adjuvanted vaccine caused 2- and 1.8-fold increase (p
h
 < 0.001, p
h
 = 0.040), and 
split vaccine caused 2.3- and 1.8-fold increase (p
h
 < 0.001, p
h
 = 0.050) compared to control, 
respectively, in women with medium and high AB level.
Analysis of TLR8-expressing cells showed interesting results (Table 2, Figure 3). This receptor 
plays important role in recognition of viral single-stranded RNA. Analysis revealed a significant 
increase in the number of these cells in PBMC culture dependent on vaccine type (F = 138.59, 
p < 0.001, q < 0.001). All vaccines induced increase in the number of TLR8-positive granu-
locytes. This parameter increased 1.6-fold after incubation with subunit vaccine (p < 0.001), 
twofold after incubation with adjuvanted vaccine (p < 0.001), and 1.7-fold after incubation with 
split vaccine (p < 0.001) compared to control. Adjuvanted vaccine was 1.3-fold more effective 
than subunit vaccine (p < 0.001) and 1.2-fold more effective than split vaccine (p < 0.001).
Differences in the number of TLR8+ cells dependent on vaccine type were detected in all groups 
of volunteers, regardless of the baseline anti-influenza AB level (F = 35.99, p < 0.001, q < 0.001 – 
low AB level, F = 76.10, p < 0.001, q < 0.001 – medium AB level, F = 116.13, p < 0.001, q < 0.001 – high 
AB level) (Figure 4). In women with low, medium and high serum AB level, subunit vaccine 
induced 1.7-fold (p
h
 < 0.001), 1.5-fold (p
h
 < 0.001), and 1.6-fold (p
h
 = 0.002) increase, respectively, 
adjuvanted vaccine caused 1.9-fold (p
h
 < 0.014), twofold (p
h
 < 0.001), and 2.1-fold (p
h
 = 0.014) 
increase, respectively, and split vaccine caused 1.8-fold (p
h
 < 0.029), 1.5-fold (p
h
 < 0.001), and 
1.7-fold (p
h
 = 0.042) increase of TLR8-expressing granulocyte number, respectively, compared 
to control. In women with medium and high serum AB level, immunoadjuvant-containing 
vaccine was, respectively, 1.3- and 1.2-fold more effective than split vaccine (p
h
 = 0.002 and 
p
h
 = 0.042), and 1.3-fold more effective than subunit vaccine (p
h
 < 0.001 и p
h
 = 0.042). In women 
with medium and high serum AB level, immunoadjuvant-containing vaccine was, respectively, 
1.3- and 1.2-fold more effective than split vaccine (p
h
 = 0.002 and p
h
 = 0.042), and 1.3-fold more 
effective than subunit vaccine (p
h
 < 0.001 и p
h
 = 0.042).
Changes in the distribution of TLR6-expressing granulocytes were similar (Table 2, Figure 3). 
Analysis showed significant increase in the number of these cells in PBMC cultures depen-
dent on vaccine type (F = 18.04, p < 0.001, q < 0.001). TLR6-expressing granulocyte number 
increased 1.5-fold after incubation with subunit vaccine, 1.3-fold after incubation with adju-
vanted vaccine, and 1.6-fold after incubation with split vaccine compared to control (p < 0.001). 
However, there were no statistically significant differences between various types of vaccines.
Analysis also showed that effect of different types of vaccines on TLR6-positive cells 
depen ded on the baseline AB level (F = 26.38, p < 0.001, q < 0.001 – low AB level; F = 11.71, 
p < 0.001, q < 0.001 – medium AB level; F = 16.57, p = 0.001, q = 0.001 – high AB level) 
(Figure 4). In women with low and medium serum AB level, subunit vaccine induced 1.6-
fold (p
h
 = 0.043) and 1.5-fold (p
h
 = 0.004) increase, respectively, adjuvanted vaccine caused 
1.2-fold (p
h
 = 0.032) and 1.3-fold (p
h
 = 0.004) increase, respectively, and split vaccine caused 
1.3-fold (p
h
 = 0.027) and 1.6-fold (p
h
 < 0.001) increase of TLR6-expressing granulocyte num-
ber, respectively, compared to control.
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In women with high serum AB level, the number of TLR6-expressing granulocytes increased 
only after incubation with split vaccine (p
h
 = 0.050).
4. Discussion
Considering that inactivated influenza vaccines have a number of drawbacks (lack of efficacy 
in certain patients [1–7], no protection against drift influenza viruses [8–11]), there is a need 
for next generation vaccines to be developed. Besides, the effect many influenza vaccines have 
on the cellular and molecular immunologic mechanisms remains poorly studied.
The effects of inactivated influenza vaccines on key effectors of innate and acquired immunity 
are being investigated at the Mechnikov Research Institute of Vaccines and Sera (Moscow). 
Various types of influenza vaccines were selected for the study. First, their effect on distribu-
tion pattern of lymphocyte subpopulations was estimated in vitro.
Analysis of the vaccine effect on the immunophenotype of lymphocytes cultured for 72 hours, 
showed activation of the innate and acquired immunity effectors: NK cells (CD16/56), NKT 
cells (CD3/CD16/56), В lymphocytes (CD45/CD20), cells with early activation marker (CD45/
CD25), Т lymphocytes with late activation marker (CD3/HLA-DR), and regulatory Т cells 
(Tregs, CD4/CD25/Foxp3). In view of this, below are characteristics of the cells that most 
actively responded to influenza vaccines added to PBMC culture.
Natural killer cells are essential to the innate immunity in influenza. Their function is to lyze 
tumor and virus-infected cells and to regulate innate and adaptive immune responses [19, 20]. 
Natural killer cells have been reported to identify influenza-infected cells through the NKp44 
and NKp46 receptors that bind influenza hemagglutinin. Natural killer cells have also been 
reported to stimulate cellular immune response, regulate eosinophil maturation, and protect 
respiratory epithelium [21]. When interacting with peripheral mononuclear cells, PO, a com-
ponent of the adjuvanted vaccine, significantly increases NK cells’ cytotoxic effect on target 
cells. The phenomenon was observed almost in all donors examined, with the increased effect 
being especially pronounced in patients with the baseline activity of NK cells at the lower 
normal limit or decreased [22].
Being phenotypically heterogenous, NKT cells duplicate the functions of NK cells and link 
innate and acquired immunity [23].
Cytotoxic T lymphocytes identify and kill virus-infected cells. Infected cells present virus 
core antigens coupled to MHC class I molecules, which ensures their identification and sub-
sequent killing by cytotoxic T lymphocytes [24, 25].
Specific cytotoxic lymphocytes cannot prevent cells from being initially infected with the 
virus, but they can restrict virus reproduction and enhance virus elimination out of the body. 
In unvaccinated adults, cytotoxic lymphocytes are crucial for clearing the body from influ-
enza. They release perforin and stimulate apoptosis of virus-infected cells [26, 27].
Efficacy of influenza vaccines is currently assessed from their ability to activate the humoral 
immune response, as recommended in WHO guidelines. We think that this assessment 
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does not adequately reflect the mechanisms of immune response to viruses. Therefore, it 
is essential to also study the cellular immunity. Immunodominance, which means that the 
immune system chooses one or more key epitopes for recognition, is an important factor for 
the development of vaccines stimulating the cellular immune response [28]. Vaccines aimed 
at producing cytotoxic T lymphocytes specific for an immunodominant epitope can signifi-
cantly narrow the cross-reactive range of immune response to various virus strains. The role 
of antigen delivery route and presentation should also be considered when developing such 
vaccines. To stimulate a strong cytotoxic immune response, an antigen should be processed 
and presented by dendritic cells and coupled to MHC class I molecules. These may occur 
either at the moment dendritic cells are being infected or transduced or when dendritic cells 
engulf apoptotic bodies from other infected cells. Thus, the induction of cytotoxic immune 
response varies from strong one (with live attenuated vaccines) to a weaker, lower one (with 
inactivated whole-virion and subunit vaccines) [21].
B lymphocytes are among the key adaptive immunity effectors in influenza, since they produce 
anti-hemagglutinin (HA) (mainly against its globular domain) virus-neutralizing antibodies that 
prevent hemagglutinin from interacting with cellular receptors. Moreover, their Fc portion con-
tributes to virion phagocytosis and to stimulation of antibody-dependent cellular cytotoxicity. 
HA amino acid sequence homology is about 80% between different strains within one subtype 
and 40–70% between strains of different subtypes. Besides, anti-neuraminidase antibodies have 
protective properties. They do not offer virus-neutralizing activity but they can inhibit neur-
aminidase enzymatic activity, which prevents the virus from spreading. Anti-neuraminidase 
antibodies also stimulate antibody-dependent cellular cytotoxicity. In addition, anti-neuramini-
dase antibodies have been shown to protect mice from H5N1 influenza virus [29].
Our study showed high stimulating effect of all studied influenza vaccines on B cell counts 
in PBMC culture. Adjuvanted vaccine was 1.3-fold more effective than subunit vaccine and 
1.1-fold more effective than split vaccine. That means that adjuvanted vaccine activated B cell 
proliferation more effectively than the inactivated vaccines studied.
B cells were found to produce IgA, IgG, and IgM antibody isotypes in primary infection, 
while no production of IgM antibodies was observed in secondary infection. IgM antibodies 
are capable of activating the complement cascade as well as of neutralizing the virus [21, 29]. 
Secretory immunoglobulins A protect respiratory mucosae, through which influenza enters 
the body, and are indicative of recent virus exposure. Immunoglobulins G ensure the longest 
protection against influenza [21, 30].
Comparative analysis of the vaccines studied showed that adjuvanted vaccine is more effec-
tive in stimulating NK, NKT cells and Tregs, as well. The vaccine was 1.3- and 1.1-fold more 
effective than subunit and split vaccines in increasing NK cell count, 2.1- and 1.5-fold for NKT 
cell count, 1.3- and 1.16-fold for B lymphocyte count, and 1.5- and 1.2-fold for Treg count, 
respectively. The studied vaccines were not found to activate other cell types.
Natural thymus-derived regulatory cells (nTreg) of CD4 + CD25+ surface phenotype with con-
stitutive expression of Foxp3 transcription factor responsible for their regulatory activity are one 
of the best documented cell population. Increased Treg number can possibly be explained by the 
immunoregulatory effect of PO (adjuvant)-containing vaccine. Immunoregulatory function of 
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nTreg is implemented both through cytokine secretion, such as TGF-β and IL-10, and through 
contact interaction with the effector T lymphocytes and antigen-presenting cells [31, 32].
Innate immune mechanisms are key to protection against pathogens, since they ensure 
prompt inflammatory reactions including detection of highly conservative structures, which 
are common to many microorganisms, through special receptors of broad specificity. These 
are signal PRRs, and TLRs are the most important of them [33–36].
Having recognized a specific pattern, PRRs initiate a series of signal cascades, which make 
the first line of defense against microorganisms. Besides, these signals initiate maturation of 
dendritic cells, which prepare the second line of immune response to the infection, known as 
acquired immunity. Thus, TLRs contribute to the regulation of innate and acquired immunity. 
Currently known are 11 types of TLRs in humans and 13 types in mice [37, 38]. Four of them 
(TLR3, TLR7, TLR8, and TLR9) recognize virus RNA and DNA. TLRs have an established role 
in physiological regulation of pro-inflammatory cytokine production, which are required for 
immune response to infections caused by bacteria, fungi, and viruses [39]. Inflammation is 
known to be directly associated primarily with neutrophils, which express almost all identi-
fied TLRs, as it has been shown recently. This explains the importance of TLRs in neutrophil 
activity regulation: LPS-induced TLR4 activation induces the production of pro-inflammatory 
cytokines and chemokines (IL-1β, IL8, and TNFα); TLR2, TLR4, and TLR9 stimulation is 
accompanied by respiratory burst and changed expression of adhesion molecules [40, 41].
The study of the effect influenza vaccine has on TLR-positive cell (granulocyte) expression 
gave the following results.
Patients with initially different anti-influenza AT titers in vitro showed statistically significant 
differences in TLR3, TLR8, and TLR9-expressing cell counts, depending on the type of influ-
enza vaccine added to leukocyte culture.
All the influenza vaccines studied, caused a statistically significant (p < 0.05) increase in 
TLR2-, TLR6-, TLR8-, and TLR9-positive granulocyte counts in PBMC culture, compared to 
non-stimulated cells.
Subunit vaccine showed statistically significant (p < 0.001) stimulating effect on the expression 
of TLR4-positive granulocytes, compared to control group and split vaccine. TLR4 is known 
to be an important regulator of neutrophil survival [40–42].
Split vaccine provided better increase in TLR3- (p = 0.008) and TLR9- (p = 0.001) positive cell 
counts, compared to subunit vaccine. Both vaccines had similar effect on TLR8+ granulocyte 
proliferation. TLR3 is an important receptor in recognition of viral double-stranded RNA 
generated during replication [43]. TLR3 expression by CD4+ и CD8+ lymphocytes is known 
to be accompanied by their activation, which allows them to get directly involved in various 
types of immune response [44].
Dendritic cell activation has been reported to occur predominantly with TLR2, TLR3, TLR4, 
TLR7, and TLR9. TLRs are effective contributors to APC activation, not only because they 
induce pro-inflammatory cytokine production, but also because they enhance expression 
of various co-stimulating molecules required for effective antibody recognition [45, 46]. 
Moreover, TLRs control dendritic cell maturation and antigen-presenting function [47]. 
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Influenza vaccines have been reported to activate innate effectors—the first line of defense to 
infection—dendritic cells, both myeloid and lymphoid lineages [48]. TLR3 plays an important 
part in cross-priming of naive CD8 T cells that differentiate to cytotoxic T cells [49, 50]. They 
are key to killing virus-infected cells. TLR3 expressed on dendritic cells is also essential for 
NK cell activation via INAM molecule [51].
Adjuvanted vaccine showed high induction potential with respect to TLR9- and TLR8-expressing 
cells, compared to subunit vaccine (p = 0.012 and p < 0.001, respectively) and split vaccine 
(p = 0.003 and p < 0.001, respectively). TLR8 has been found to recognize viral single-stranded 
RNA and to be a specific receptor responsible for influenza virus recognition [45, 52]. The 
increased TLR8-positive cell count in this study can be attributed to the co-stimulating effect 
of the adjuvant in the adjuvanted vaccine.
TLR9 along with TLR2 and TLR4 are involved in the regulation of B lymphocyte activation, 
proliferation, differentiation, and survival (this is considered an alternative pathway of B lym-
phocyte activation) [53]. TLR9 is also supposed to be a PRR key to influenza identification and 
binding, while recognition of influenza virions by TLR7/8 is significant for the induction of 
protective immune response to main antigens (hemagglutinin) [54].
Two different intracellular signaling systems are generally recognized at the moment. One 
of them involves TLR2, TLR4, TLR5, TLR7, TLR9 and intracellular molecules MyD88, IRAK, 
TRAF, NFkB. This intracellular signaling system usually activates an early pro-inflammatory 
response. The other intracellular system involves TLR3, TLR4, (might involve TLR7 and 
TLR8), adaptor protein TRIF and intracellular proteins TRAM, TBK1, and IRF3. This signaling 
system ensures the activation of anti-virus response. TLR3 is the key component of this signal-
ing pathway, since it interacts with double-stranded viral RNA. TLR4 is equally effective in 
the activation of both intracellular signaling systems. Thus, there are two important types 
of innate immune responses. The first type activates antibacterial protection along with the 
tissue inflammation. The second type provides type I interferon-mediated antiviral response, 
with interferon being the primary antiviral mediator in innate immunity [55].
5. Conclusion
Thus, the studies have shown that influenza vaccines activate cellular immunity effectors as 
well as induce humoral immune response. PO-containing adjuvanted vaccine showed the 
strongest capability of inducing the cellular response, among the three vaccines studied.
Influenza vaccines in vitro induced an increase in the number of the innate and acquired 
immunity effectors: NK cells, NKT cells, В lymphocytes, cells with early activation marker, Т 
lymphocytes with late activation marker, and regulatory Т cells.
Despite the fact that influenza vaccines must activate endosomal receptors, they cause non-
specific activation of the surface TLRs. This might be due to the influence exerted by antigen 
complexes contained in influenza vaccines of various types and due to the presence of an 
adjuvant in one of the vaccines studied. These vaccines activate TLR signaling cascade and, 
thus, can probably stimulate key effectors of the innate (DC, NK, and NKT cells) and adaptive 
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(CTL, B lymphocytes) immunity, which provide antiviral effect and induce body’s own 
defense mechanisms against microbial infection.
6. Vaccination against influenza: the prospect of using adjuvants
The flu is widespread around the world and causes seasonal epidemics, which result in the 
death of hundreds of thousands of people each year [56]. Complications leading to morbidity 
and mortality following infection are predominantly observed in high-risk groups: children 
of early age, people with chronic diseases and pregnant women [57]. According to WHO, 
globally annual epidemics result in 3,000,000–5,000,000 cases of severe disease and approxi-
mately 250,000–500,000 deaths [58].
The vaccination is the most effective tools for preventing of influenza and, as a consequence, 
reducing the number and severity of post-infectious complications. Inactivated influenza vac-
cines received the most widely used, due to its high efficiency and low reactogenicity. But, 
at the same time, inactivated influenza vaccines, including seasonal trivalent vaccines, used 
for the annual prevention of influenza in the autumn-winter period, are not without some 
limitations. These vaccines are not enough (effective) immunogenic in vaccinating a number 
of population groups - small children, pregnant women, the elderly, people with various 
chronic diseases that are considered to be influenza risk groups. Also, inactivated influenza 
vaccines are not sufficiently protected against antigenically different strains (drift and heter-
ologous) of the influenza virus that are not contained in the vaccine. In addition, the capacity 
of all manufacturers may not be sufficient to provide mass vaccine prevention around the 
world, especially in the event of a pandemic [59–61].
To increase the immunogenicity of inactivated influenza vaccines, adjuvants (immunoadju-
vants) have been proposed. With the use of adjuvants, it is possible to increase the immuno-
genicity of influenza vaccines against a set of antigenically different strains. Adjuvants in the 
influenza vaccine can also provide efficacy in the immunization of various population groups, 
including at-risk groups. In addition, a significant increase in the immunogenicity of the vac-
cine due to the adjuvant will allow the transition to simple (single) immunization regimens, 
as well as reduce the dose of the antigen (hemagglutinin). This is especially important for 
pre-pandemic vaccines, because with the same production capacity, more vaccines will be 
obtained - and as a result, more people are immunized [59, 61].
The action of most adjuvants is based on the prolongation of the AG action, which is provided 
by the creation of a “depot” of the AG, which slows its absorption. Due to the sorption of 
AG on certain carriers, the antigen is held in places necessary for exposure of the antigen to 
antigen presenting cells and lymphocytes. Such an effect occurs when using aluminum alum, 
immunostimulating complexes, an oil microemulsion [62].
The effect of deposition is also achieved through the use of liposomes [63]. Adjuvants that 
primarily affect the phagocytic link of the immune system include polyelectrolytes, includ-
ing PO. Structural association of the AG and polymer-immunostimulant enhances the 
migration of phagocytes, the functional activity of macrophages in tissues and increases 
their processing activity [64].
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The action of adjuvants depends on the initial immune status of the organism preceding the 
vaccination. Adjuvants accelerate development and increase the level of immune response, 
increase the duration of its retention. Long rise and a slow decrease in the intensity of post-
vaccination immunity is characteristic of adjuvanted vaccines. At the same time, a reliable 
immune response is achieved with the help of small doses of AG and a small number of 
injections of the vaccine [63].
PO possesses expressed immune modulating effects acting first of all on the innate immunity 
factors such as monocytic-macrophagal system cells, neutrophils and NK-cells and inducing 
their activation under initially reduced functions. Flow cytochemistry data showed that PO 
does interact with three lymphocyte subclasses, predominantly binds with monocytes and 
neutrophils and to a lesser extent with lymphocytes, enhancing intracellular H2O2 produc-
tion. Hydrogen peroxide being the secondary messenger activates the transcriptional NF-kB 
factor that is the participant of the cytokines synthesis regulation. The enhancement of the 
pro-inflammatory cytokines IL-1β, IL6, TNF-α synthesis takes place. Activation by PO cells 
of monocytic-macrophagal cluster and natural killers promotes mobilization of both cellular 
and humoral immunity. Finally, all immunity starts up for adequate response development 
similarly to that as it occurs in natural way [65].
Besides its own clinical application as independent drug, Polyoxidonium is used as immu-
noadjuvant in new generation vaccines and is a compound in subunit adjuvanted Grippol 
family vaccines since 1997 when first Grippol® vaccine was registered in Russian market. 
Due to Polyoxidonium, all Grippol family vaccines contain 3-times lower antigen content in 
one immunizing dose - 5 mcg per strain, in comparison to 15 mcg per strain in other subunit 
and split influenza vaccines. This provides Grippol family vaccines with higher safety profile. 
Today Grippol vaccines are approved and especially recommended for vaccination of cohorts 
that previously were considered to be not vaccinated (patients with allergic conditions, sub-
jects with chromic somatic diseases, individuals with different immune deficiencies), and chil-
dren from 6 months of age, and pregnant women. These recommendations were made based 
on relevant clinical trials results followed by many years practical mass vaccine application 
experience [66, 67].
Annual vaccination with the “yearly adapted vaccine” is an effective means of prevention 
and control of influenza in immunocompetent individuals, even in those with a known poor 
antibody response. In addition to the development of protective antibodies after vaccina-
tion, the induction of cell-mediated immunity is considered to be of critical importance [68]. 
Recent researches concerning the response to influenza vaccination in patients with CVID and 
unclassified antibody deficiency have shown that while the humoral immune response was 
strongly impaired, a T cell response against the vaccine was detected in most patients [69].
Seasonal vaccines primarily work through the induction of neutralizing antibodies against 
the principal surface antigen HA. This important role of HA-specific antibodies explains 
why previous pandemics have emerged when new HAs have appeared in circulating human 
viruses. It has long been recognized that influenza virus-specific CD4(+) T cells are important 
in protection from infection through direct effector mechanisms or by providing help to B 
cells and CD8(+) T cells. However, the seasonal influenza vaccine is poor at inducing CD4(+) 
T cell responses and needs to be combined with an adjuvant facilitating this response [70].
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Protective immunity induced by SF-10 (synthetic human pulmonary surfactant with a car-
boxy vinyl polymer as a viscosity improver) against lethal influenza virus infection was 
partially and predominantly suppressed after depletion of CD8+ and CD4+ T cells (induced 
by intraperitoneal injection of the corresponding antibodies), respectively, suggesting that 
CD4+ T cells predominantly and CD8+ T cells partially contribute to the protective immunity 
in the advanced stage of influenza virus infection [71]. These results suggest that adjuvants 
can promote effective antigen delivery to antigen presenting cells, activates CD8+ T cells via 
cross-presentation, and induces cell-mediated immune responses against antigen.
Influenza infection elicits high-affinity IgA in the respiratory tract and virus-specific IgG, 
which correlates with protection. Long-lived influenza-specific T cells have also been shown 
to ameliorate disease [72]. Activation of the parameters of innate immunity is critical for the 
recognition of infection, as well as for the effectiveness of vaccination, which allows not only 
eliminating pathogens and cells with altered antigenic properties, but also having a signifi-
cant effect on the formation of adaptive immunity [73].
Development of a universal influenza vaccine currently seems to be quite workable and 
promising task. Such universal vaccines are expected to contain both antibody production 
stimulants and inductors of cellular immune response with effectors of innate and adaptive 
immunity being involved. Adjuvants may play an important part, their functions being aimed 
both at enhancing immune response to an antigen and at regulating that response [74]. Thus, 
due to the emergence of a new type of vaccine (adjuvant), in assessing the immunological 
efficacy is important not only humoral but also cellular immune response.
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RNA Ribonucleic acid
MHC Major histocompatibility complex
HA hemagglutinin
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TGF-β transforming growth factor beta
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PRRs pathogen-recognize receptors
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